Superworth

Repligen price to sales ratio RGEN

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
12.7×
10-year median
13.3×
Against its 10-year history
40th
percentile: 0 is its lowest day, 100 its highest
10-year range
7.6× to 36.4×
Peer median
6.8×

Repligen's price to sales ratio is 12.7× as of Oct 23, 2026.

That is below its ten-year median of 13.3×, close to the middle of its last ten years.

Over that time it ranged from 7.6× in May 2026 to 36.4× in Feb 2021.

The median for 10 biotech stocks of a similar size is 6.8×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far12.7×7.6×13.6×
202513.2×9.3×14.7×
202412.9×11.0×17.4×
202315.0×9.1×15.2×
202211.7×10.8×19.3×
202124.7×21.8×36.4×
202030.8×16.5×33.1×
201919.0×12.1×20.8×
201812.3×10.6×16.2×
201712.6×9.8×14.6×
201610.4×8.1×11.7×
201511.9×10.5×20.3×
201410.6×5.6×12.5×
20135.6×3.2×6.0×
20123.7×3.3×6.5×

Against its peers

Companies in Biotechnology nearest Repligen's size, closest first, today.

CompanyPrice to sales ratio
RGENRepligen12.7×
KRYSKrystal Biotech20.9×
TECHBIO-TECHNE9.4×
HALOHalozyme Therapeutics8.6×
NBIXNeurocrine Biosciences4.3×
EXELExelixis6.6×
INCYIncyte4.0×
UTHRUnited Therapeutics8.0×
ALNYAlnylam Pharmaceuticals6.2×
ADMAAdma Biologics4.7×
ONCBeOne Medicines7.0×
Peer median6.8×

Where Repligen ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Repligen

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.